PhoenixBio Co., Ltd. (TYO:6190)
Japan · Delayed Price · Currency is JPY 338.00
-4.00 (-1.17%)
Aug 27, 2026, 3:30 PM JST
PhoenixBio Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 1,423 | 1,565 | 1,541 | 1,715 | 2,124 | 1,324 | |
Revenue Growth | -4.63% | 1.56% | -10.15% | -19.26% | 60.42% | 30.70% |
Cost of Revenue | 356 | 365 | 424 | 521 | 567 | 597 |
Gross Profit | 1,067 | 1,200 | 1,117 | 1,194 | 1,557 | 727 |
Selling, General & Admin | 900 | 915 | 977 | 969 | 836 | 665 |
Research & Development | 191 | 191 | 273 | 206 | 205 | 219 |
Operating Expenses | 1,102 | 1,117 | 1,253 | 1,189 | 1,048 | 895 |
Operating Income | -35 | 83 | -136 | 5 | 509 | -168 |
Interest Expense | -4 | -4 | -5 | -2 | -3 | - |
Interest & Investment Income | 8 | 9 | 8 | 5 | 2 | - |
Currency Exchange Gain (Loss) | 38 | 30 | -25 | 17 | -9 | 23 |
Other Non Operating Income (Expenses) | 14 | 13 | 4 | 18 | 11 | 18 |
EBT Excluding Unusual Items | 21 | 131 | -154 | 43 | 510 | -127 |
Gain (Loss) on Sale of Investments | - | - | - | 17 | - | - |
Asset Writedown | - | - | -168 | -1 | - | -265 |
Other Unusual Items | - | - | -110 | - | - | - |
Pretax Income | 21 | 131 | -432 | 59 | 510 | -392 |
Income Tax Expense | 6 | 6 | 16 | 33 | 17 | -5 |
Net Income | 15 | 125 | -448 | 26 | 493 | -387 |
Net Income to Common | 15 | 125 | -448 | 26 | 493 | -387 |
Net Income Growth | - | - | - | -94.73% | - | - |
Shares Outstanding (Basic) | 4 | 4 | 4 | 4 | 3 | 3 |
Shares Outstanding (Diluted) | 4 | 4 | 4 | 4 | 5 | 3 |
Shares Change | 0.48% | 0.50% | 6.95% | -25.42% | 53.57% | 2.11% |
EPS (Basic) | 3.69 | 30.75 | -110.76 | 6.88 | 145.13 | -117.20 |
EPS (Diluted) | 3.69 | 30.75 | -110.76 | 6.88 | 97.29 | -117.20 |
EPS Growth | - | - | - | -92.93% | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | 56 | -94 | -110 | 270 | 10 |
Free Cash Flow Per Share | - | 13.78 | -23.24 | -29.09 | 53.25 | 3.03 |
Gross Margin | 74.98% | 76.68% | 72.48% | 69.62% | 73.30% | 54.91% |
Operating Margin | -2.46% | 5.30% | -8.82% | 0.29% | 23.96% | -12.69% |
Profit Margin | 1.05% | 7.99% | -29.07% | 1.52% | 23.21% | -29.23% |
Free Cash Flow Margin | - | 3.58% | -6.10% | -6.41% | 12.71% | 0.76% |
EBITDA | -0.75 | 116 | -108 | 30 | 532 | -82 |
EBITDA Margin | -0.05% | 7.41% | -7.01% | 1.75% | 25.05% | -6.19% |
D&A For EBITDA | 34.25 | 33 | 28 | 25 | 23 | 86 |
EBIT | -35 | 83 | -136 | 5 | 509 | -168 |
EBIT Margin | -2.46% | 5.30% | -8.82% | 0.29% | 23.96% | -12.69% |
Effective Tax Rate | 28.57% | 4.58% | - | 55.93% | 3.33% | - |